Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Epistemonikos ID: f9665125adc4c460c680486ad2c506131bc6ad22
First added on: May 20, 2024